Xcout Intel
Amalgent Therapeutics, LLC
Amalgent Therapeutics develops fixed-dose combination therapies that pair opioids with dopamine-modulating adjuvants to provide safe pain management. The company's lead program, AMGT-0220, is designed to reduce required opioid doses, mitigate tolerance development, and lower reward signaling to help patients recover without the risks of conventional opioid treatments.
Subscribe to see Amalgent Therapeutics, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Amalgent Therapeutics, LLC at a glance
Amalgent Therapeutics, LLC is a biotechnology company headquartered in United States. Its most recent funding round raised $200,000 in April 2022. Xcout tracks 4 named people at Amalgent Therapeutics, LLC, including Andrew Graham (Chief Finance Officer).
Amalgent Therapeutics, LLC leadership
- Andrew GrahamChief Finance Officer
- Gerald KleinChief Medical Officer
- Sam TetlowCo-founder President, Executive Chair
- Malcolm MeynCo-founder and Chief Scientific Officer
Amalgent Therapeutics, LLC funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $200,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Amalgent Therapeutics, LLC competitors
A few of Amalgent Therapeutics, LLC's closest competitors — see the full list of competitors and alternatives →
Daya CNS, LLC is a preclinical biopharmaceutical company that develops a proprietary non-opioid pyridoindole platform for the treatment of chronic pain, substance abuse disorders, and neuropsychiatric conditions. Its product pipeline includes small molecule medications such as DDD-028 for neuropathic and inflammatory pain, DDD-024 for addiction, and DDD-016 for neuropsychiatric disorders, serving patients with unmet medical needs in neurology and addiction medicine.
Semnur Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, non-opioid products for pain management.
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
Centrexion Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel non-opioid therapeutics for the treatment of chronic pain and painful conditions.
Undaunted Bio, Inc. is an AI-driven drug repurposing company headquartered in Pittsburgh, United States, focused on treatments for neuropathic pain.
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
Get Amalgent Therapeutics, LLC's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Amalgent Therapeutics, LLC in Xcout Intel
- 4 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access